Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

Non-small cell lung cancers (NSCLCs) with activating mutations in the kinase domain of the epidermal growth factor receptor (EGFR) demonstrate dramatic, but transient, responses to the reversible tyrosine kinase inhibitors gefitinib (Iressa) and erlotinib (Tarceva). Some recurrent tumors have a comm...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Kwak, Eunice L., Sordella, Raffaella, Bell, Daphne W., Godin-Heymann, Nadia, Okimoto, Ross A., Brannigan, Brian W., Harris, Patricia L., Driscoll, David R., Fidias, Panos, Lynch, Thomas J., Rabindran, Sridhar K., McGinnis, John P., Wissner, Allan, Sharma, Sreenath V., Isselbacher, Kurt J., Settleman, Jeffrey, Haber, Daniel A.
Formato: Artigo
Idioma:Inglês
Publicado em: National Academy of Sciences 2005
Assuntos:
Biological Sciences
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC1129023/
https://ncbi.nlm.nih.gov/pubmed/15897464
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.0502860102
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados